Neuromelanin-bound ferric iron as an experimental model of dopaminergic neurodegeneration in Parkinson's disease

Federow, 2005, Neuromelanin in human dopamine neurons: comparison with pheripheral melanins and relevance to Parkinson's disease, Prog Neurobiol, 75, 109, 10.1016/j.pneurobio.2005.02.001 Hirsch, 1988, Melanized dopamine neurons are differentially susceptible to degeneration in Parkinson's disease, Nature, 334, 345, 10.1038/334345a0 Jellinger, 1989, Pathology of Parkinson's syndrome, vol. 88, 47 Braak, 2001, α-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei, Acta Neuropathol, 101, 195, 10.1007/s004010000247 Gerlach, 1994, Altered brain metabolism of iron as a cause of neurodegenerative diseases?, J Neurochem, 63, 793, 10.1046/j.1471-4159.1994.63030793.x Berg, 2001, Brain iron pathways and their relevance to Parkinson's disease, J Neurochem, 79, 225, 10.1046/j.1471-4159.2001.00608.x Götz, 2004, The relevance of iron in the pathogenesis of Parkinson's disease, Ann NY Acad Sci, 1012, 193, 10.1196/annals.1306.017 Sofic, 1988, Increased iron (III) and total iron content in post-mortem substantia nigra of parkinsonian brain, J Neural Transm, 74, 199, 10.1007/BF01244786 Gerlach, 2006, Potential sources of increased iron in the substantia nigra of parkinsonian patients, J Neural Transm, 133, 10.1007/978-3-211-45295-0_21 Lopiano, 1999, Iron and neuromelanin in Parkinson's disease, J Neural Transm, 106, XXIV Double, 1999, The significance of neuromelanin for neurodegeneration in Parkinson's disease, Drug News Perspect, 12, 333 Double, 2003, Iron binding characteristics of neuromelanin of the human substantia nigra, Biochem Pharmacol, 66, 489, 10.1016/S0006-2952(03)00293-4 Gerlach, 1995, Mössbauer spectroscopic studies of human neuromelanin isolated from the substantia nigra, J Neurochem, 65, 923, 10.1046/j.1471-4159.1995.65020923.x Shima, 1997, Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study, Free Radic Biol Med, 23, 110, 10.1016/S0891-5849(96)00623-5 Shamoto-Nagai, 2006, Neuromelanin induces oxidative stress in mitochondria through release of iron: mechanism behind the inhibition of 26S proteasome, J Neural Transm, 113, 633, 10.1007/s00702-005-0410-5 Li, 2005, Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells, J Neurochem, 95, 599, 10.1111/j.1471-4159.2005.03404.x Offen, 1999, Dopamine–melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease, Neurosci Lett, 260, 101, 10.1016/S0304-3940(98)00950-1 Nguyen, 2002, Synthetic neuromelanin is toxic to dopaminergic cell cultures, J Neural Transm, 109, 651, 10.1007/s007020200054 Shamoto-Nagai, 2004, Neuromelanin inhibits enzymatic activity of 26 proteasome in human dopaminergic SH-SY5Y cells, J Neural Transm, 111, 1253, 10.1007/s00702-004-0211-2 McNaught, 2003, Altered proteasomal function in sporadic Parkinson's disease, Exp Neurol, 179, 38, 10.1006/exnr.2002.8050 Double, 2003, The dopamine receptor agonist lisuride attenuates iron-mediated dopaminergic neurodegeneration, Exp Neurol, 184, 530, 10.1016/j.expneurol.2003.08.006 Gerlach, 1996, Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man, J Neural Transm, 103, 987, 10.1007/BF01291788 Riederer, 1976, Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis, J Neural Transm, 38, 277, 10.1007/BF01249445 Halliday, 1996, Midbrain neuropathology in idiopathic Parkinson's disease and diffuse Lewy body disease, J Clin Neurosci, 3, 52, 10.1016/S0967-5868(96)90083-1